Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. commercializes ophthalmic disease management products in North America, with a portfolio used in dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions and retina diseases. Its recurring news includes financial results and stockholder letters, commercial product updates for therapies such as VEVYE, ILEVRO, IOPIDINE and TRIESENCE, and distribution arrangements supporting U.S. product availability.
Company updates also cover reimbursement and regulatory developments, scientific presentations in ophthalmology, clinical development for label expansion, product launches and capital actions such as senior unsecured notes. Harrow reports through branded ophthalmic pharmaceuticals and ImprimisRx, reflecting both commercial products and specialty ophthalmic medication operations.
Harrow (Nasdaq: HROW) has selected LogiCare3PL as its U.S. distribution partner for Harrow's ophthalmic disease management solutions. Effective Feb 1, 2026, LogiCare3PL will provide both non-title logistics and 3PL title distribution across the U.S., meeting Harrow's rapid onboarding needs.
LogiCare3PL completed Harrow's onboarding in four weeks, supporting faster, cost-effective market access while maintaining high-touch customer engagement and continuity of supply.
Harrow (Nasdaq: HROW) priced a private offering of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due September 15, 2030. The notes will be issued at 100.25% and treated as a single series with an existing $250.0 million 2030 note issue.
The offering is expected to close on March 27, 2026, interest accrues from March 15, 2026, and net proceeds are for general corporate purposes including product development and growth initiatives.
Harrow (Nasdaq: HROW) intends to offer an additional $50.0 million aggregate principal of its 8.625% senior unsecured notes due 2030 as an add-on to the existing $250.0 million series issued Sept 12, 2025.
Proceeds are planned for general corporate purposes, including product launches, development, and strategic opportunities; the offering targets qualified institutional buyers and non-U.S. persons under Regulation S.
Harrow (Nasdaq: HROW) announced three scientific abstracts accepted for presentation at the ASCRS 2026 Annual Meeting, April 10–13 in Washington, D.C. The studies feature Harrow commercial products VEVYE 0.1% and ILEVRO 0.3% covering dry eye disease and post-cataract surgery outcomes.
Presentations occur April 11–12 and will release detailed data at session times listed by the company.
Harrow (Nasdaq: HROW) will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 AM ET in Miami, Florida. The management presentation will be webcast live on the company website, with a replay available for approximately 90 days after the event.
Harrow (Nasdaq: HROW) announced FDA clearance of an IND to support a planned Phase 3 trial of TRIESENCE 40 mg/mL for ocular inflammation and pain following cataract surgery. The randomized, placebo-controlled, double-masked study will enroll ~250 patients (2:1 randomization) with primary endpoints at Day 14 (anterior chamber cells) and Day 8 (pain).
Harrow expects study initiation in Q1 2026 and enrollment to start in Q2 2026, aiming to generate data to potentially expand TRIESENCE’s label and strengthen its surgical care role.
Harrow (Nasdaq: HROW) reported record Q4 revenue of $89.1M (up 33% YoY) and full-year 2025 revenue of $272.3M (up 36% YoY). GAAP net income was $6.6M in Q4 while full-year GAAP showed a $5.1M net loss. Adjusted EBITDA was $24.2M in Q4 and $61.9M for 2025. Harrow generated $43.9M operating cash flow in 2025 and ended the year with $72.9M cash. 2026 guidance: revenue $350M–$365M and Adjusted EBITDA $80M–$100M.
Harrow (Nasdaq: HROW) will report fourth quarter and year-end 2025 financial results on March 2, 2026 after market close and will post a Q4 Letter to Stockholders on its Investors webpage.
The company will host a conference call and live webcast at 8:00 a.m. ET on March 3, 2026, with a replay available on the website for one year.
Harrow (Nasdaq: HROW) launched PharmaPack, a Direct-to-Prescriber cash-pay program on Feb 17, 2026, offering FDA-approved ophthalmic kits as affordable alternatives to compounded products.
Initial availability covers California, Mississippi, Arkansas, Connecticut, and Alabama, with nationwide expansion planned in the coming weeks.
OSRX (HROW) confirmed it remains fully licensed, FDA-registered and operational in California and all 50 states following a competitor's market exit.
According to the company, ImprimisRx voluntarily forfeited its California license on Feb 1, 2026 and agreed to pay an administrative fine of approximately $157,000 to the California Board of Pharmacy. OSRX says it supports thousands of ophthalmologists and optometrists and offers direct-to-patient and direct-to-facility dispensing of compounded ophthalmic medications.